A new statistical analysis suggests a possible, though currently unverified, correlation between the consumer representatives serving on Food and Drug Administration panels and the drug manufacturers actively funding their advocacy groups, experts cautioned Tuesday.
The data, published this week in a JAMA paper, examined FDA advisory committee meetings over a 20-year period. Researchers noted that nearly 40 percent of the regulatory sessions included at least one patient representative with financial ties to pharmaceutical companies, though authors of the study were quick to emphasize that the findings are purely observational and do not establish causation between accepting corporate money and possessing it.
We are seeing an elevated incidence of industry-backed advocates voting to approve industry-backed drugs, but until we can isolate these variables in a controlled, double-blind clinical trial, it would be premature to classify this as a conflict of interest.
The FDA issued a statement following the report, advising the public that more research is needed before determining whether a multinational pharmaceutical conglomerate paying a patient advocacy group constitutes a financial relationship. Regulators stressed that the 40 percent figure represents a relatively small sample size when viewed alongside the total number of medications on the market, noting that eliminating industry-funded voices could disrupt the routine functioning of panels tasked with approving new treatments.
Until further longitudinal studies are completed, health officials recommend treating any direct monetary transfers between drugmakers and supposedly independent patient representatives as localized, asymptomatic events that pose no immediate threat to the regulatory process.